MedTrace Logo

Human Epilepsy Project 2: Resistant Focal Seizures Study

NCT03531008 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 157

Last updated 2023-09-18

No results posted yet for this study

Summary

The HEP2 study is designed to better understand the challenges of living with focal seizures that do not respond to medication, by following 205 people with medication-resistant focal epilepsy over two years to measure changes in health status, healthcare costs, quality of life, and biomarkers of epilepsy severity and treatment response.

Conditions

Sponsors & Collaborators

  • The Epilepsy Study Consortium

    collaborator OTHER

  • UCB Biopharma S.P.R.L.

    collaborator INDUSTRY

  • Epilepsy Foundation of America

    lead OTHER

Principal Investigators

  • Brandy Fureman, PhD · Epilepsy Foundation

  • Jacqueline French, MD · New York University

  • Ruben Kuzniecky, MD · Northwell Health

  • Daniel Lowenstein, MD · University of California, San Francisco

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-07
Primary Completion
2022-07-30
Completion
2022-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03531008 on ClinicalTrials.gov